+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Diarrhea Drug Pipeline Analysis Report 2025

  • PDF Icon

    Drug Pipelines

  • 200 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102811
Diarrhea is a condition characterized by the frequent passage of loose or watery stools, often caused by infections, food intolerance, or underlying health issues. Globally, diarrhea alone accounts for approximately 0.5 million deaths among children under the age of five annually and stands as the second most common cause of mortality in this age group. The diarrhea drug pipeline is witnessing significant advancements, with improved therapies and innovative diarrhea therapeutics under development. The growing focus on enhancing treatment efficacy, addressing antimicrobial resistance, and improving supportive care is expected to drive substantial growth in the pipeline.

Report Coverage

The Diarrhe Drug Pipeline Insight Report by the publisher gives comprehensive insights into diarrhea therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for diarrhea. The diarrhea report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The diarrhea pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with diarrhea treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to diarrhea.

Diarrhea Drug Pipeline Outlook

Diarrhea is a condition characterized by frequent, loose, or watery bowel movements. It occurs when the digestive system fails to absorb fluids properly or when excess fluids are secreted into the intestines. Causes include infections, food intolerance, medications, and digestive disorders. It can lead to dehydration if left untreated, especially in young children and older adults.

Diarrhea is treated by maintaining hydration through oral rehydration solutions (ORS) to prevent dehydration. Medications like loperamide may reduce symptoms, while antibiotics are prescribed for bacterial infections. Dietary adjustments, such as consuming bland foods, also aid recovery. In severe cases, intravenous fluids may be required.

Diarrhea Epidemiology

Globally, diarrhea causes approximately 0.5 million deaths annually among children under five, making it the second leading cause of mortality in this group. Around 1.7 billion childhood diarrhea cases are recorded each year. In the United States, diarrheal illnesses account for 178.8 million cases annually, leading to 474,000 hospitalizations and 5,000 deaths. In Japan, chronic diarrhea affects approximately 3%-5% of the population, with higher prevalence among men, while India records 120,000 child deaths yearly.

Diarrhea - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of diarrhea drug candidates based on several segmentations, including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

  • Small Molecules
  • Biologics
  • Probiotics
  • Vaccines
  • Peptides
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

Diarrhea - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total diarrhea clinical trials.

Diarrhea - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the diarrhea pipeline analysis include small molecules, biologics, probiotics, vaccines, peptides, and others. The diarrhea report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for diarrhea.

Diarrhea Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the diarrhea drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed diarrhea therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in diarrhea clinical trials:
  • GlaxoSmithKline
  • Immuron Ltd.
  • RedHill Biopharma Limited
  • Lumen Bioscience, Inc.
  • CinPhloro Pharma, LLC
  • Tasly Pharmaceutical Group Co., Ltd.
  • Chongqing Peg-Bio Biopharm Co., Ltd.
  • AbbVie
  • Lallemand Health Solutions
  • Vedanta Biosciences, Inc.
  • Crinetics Pharmaceuticals Inc.
  • Pfizer

Diarrhea Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for diarrhea. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of diarrhea drug candidates.

Drug: Probiotic Formulation

A probiotic formulation is being investigated in a Phase IV clinical trial sponsored by Lallemand Health Solutions. The study aims to evaluate the safety and efficacy of a probiotic formulation in alleviating abdominal pain, abnormal defecation, anxiety, and depression and improving the quality of life in adults with irritable bowel syndrome with diarrhea (IBS-D). The trial is expected to be completed by November 2024

Drug: Changkang Granules

Changkang Granules, sponsored by Tasly Pharmaceutical Group Co., Ltd, is currently undergoing a Phase III clinical trial to evaluate its efficacy and safety in treating irritable bowel syndrome with predominant diarrhea. This randomized, double-blind, placebo-controlled study aims to assess the therapeutic potential of Changkang Granules, a traditional Chinese medicine, with an estimated completion date of December 2026.

Drug: Rifamycin SV-MMX

Rifamycin SV MMX, marketed as Aemcolo®, is a non-systemic, delayed-release antibiotic designed to target the lower intestine using Cosmo Pharmaceuticals' MMX® technology for controlled drug delivery. Rifamycin SV MMX is currently being evaluated in a Phase II clinical trial, conducted by RedHill Biopharma Limited, to assess its safety and efficacy in treating traveler's diarrhea in children aged 6 to 11 years. This double-blind study involves 142 participants receiving either Rifamycin SV MMX or a placebo with oral rehydration therapy (ORT).

Reasons To Buy This Report

The Diarrhea Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for diarrhea. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into diarrhea collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Diarrhea - Pipeline Insight Report

  • Which companies/institutions are leading the diarrhea drug development?
  • What is the efficacy and safety profile of diarrhea pipeline drugs?
  • Which company is leading the diarrhea pipeline development activities?
  • What is the current diarrhea commercial assessment?
  • What are the opportunities and challenges present in the diarrhea drug pipeline landscape?
  • What is the efficacy and safety profile of the diarrhea pipeline drugs?
  • Which company is conducting major trials for diarrhea drugs?
  • Which companies/institutions are involved in diarrhea collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in diarrhea?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Diarrhea
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Diarrhea
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Diarrhea: Epidemiology Snapshot
5.1 Diarrhea Incidence by Key Markets
5.2 Diarrhea - Patients Seeking Treatment in Key Markets
6 Diarrhea: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Diarrhea: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Diarrhea, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 Drug Pipeline Comparative Analysis
9.1 List of Diarrhea Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Diarrhea Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Probiotic Formulation
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: Changkang Granules
10.2.3 Other Drugs
11 Diarrhea Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Rifamycin SV-MMX
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: CIN-103
11.2.3 Other Drugs
12 Diarrhea Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: FT1
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Diarrhea Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Diarrhea, Key Drug Pipeline Companies
14.1 GlaxoSmithKline
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Immuron Ltd.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 RedHill Biopharma Limited
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Lumen Bioscience, Inc.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 CinPhloro Pharma, LLC
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Tasly Pharmaceutical Group Co., Ltd.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Chongqing Peg-Bio Biopharm Co., Ltd.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 AbbVie
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
14.9 Lallemand Health Solutions
14.9.1 Company Snapshot
14.9.2 Pipeline Product Portfolio
14.9.3 Financial Analysis
14.9.4 Recent News and Developments
14.10 Vedanta Biosciences, Inc.
14.10.1 Company Snapshot
14.10.2 Pipeline Product Portfolio
14.10.3 Financial Analysis
14.10.4 Recent News and Developments
14.11 Crinetics Pharmaceuticals Inc.
14.11.1 Company Snapshot
14.11.2 Pipeline Product Portfolio
14.11.3 Financial Analysis
14.11.4 Recent News and Developments
14.12 Pfizer
14.12.1 Company Snapshot
14.12.2 Pipeline Product Portfolio
14.12.3 Financial Analysis
14.12.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products